Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism

Abdul Halim Abdul Gafor, Rashidi Saidin, Chee Yean Loo, Rozita Mohd, Soehardy Zainudin, Shamsul Azhar Shah, Kong Chiew Tong Norella

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Aim: Secondary hyperparathyroidism (SHPT) is common among haemodialysis patients. Intensive treatment with calcitriol is often complicated by hypercalcaemia, hyperphosphataemia and elevated calcium phosphorus (Ca X PO 4) product. Paricalcitol is a vitamin D analogue developed to overcome some of the limitations of calcitriol therapy. The study objectives were to compare the response of intact parathyroid hormone (iPTH) and the incidence of hypercalcaemia, hyperphosphataemia and elevated Ca X PO4 product in patients with severe SHPT treated with either i.v. calcitriol or i.v. paricalcitol. Methods: This was a single centre randomized open label study. Patients with serum intact iPTH of 50 pmol/L or more were randomized to receive either i.v. calcitriol (0.01 ug/kg) or i.v. paricalcitol (0.04 ug/kg) during every haemodialysis treatment. Serum iPTH, calcium, phosphorus and alkaline phosphatase were measured at the beginning of the study and every 3 weeks for 12 weeks. Results: Twenty-five patients were enrolled into the study - 12 were randomized into the calcitriol group and 13 into the paricalcitol group. There were no differences in the baseline study parameters between both groups. Serum iPTH levels were significantly reduced (P = 0.003) only in the paricalcitol group but not in the calcitriol group (P = 0.101). On the other hand, serum calcium levels were significantly increased only in the calcitriol group (P = 0.004 vs P = 0.242). Serum phosphorus, alkaline phosphatase and Ca X PO4 product were not different. Conclusion: Intravenous paricalcitol may be superior to i.v. calcitriol for the treatment of severe SHPT in our chronic haemodialysis population. A larger randomized controlled trial is indicated to confirm these initial findings.

Original languageEnglish
Pages (from-to)488-492
Number of pages5
JournalNephrology
Volume14
Issue number5
DOIs
Publication statusPublished - Aug 2009

Fingerprint

Secondary Hyperparathyroidism
Calcitriol
Renal Dialysis
Parathyroid Hormone
Phosphorus
Serum
Hypercalcemia
Calcium
Alkaline Phosphatase
paricalcitol
Therapeutics
Vitamin D
Randomized Controlled Trials
Incidence

Keywords

  • Calcium
  • Calcium phosphorus product
  • Haemodialysis
  • Parathyroid hormone
  • Phosphate

ASJC Scopus subject areas

  • Nephrology

Cite this

Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism. / Abdul Gafor, Abdul Halim; Saidin, Rashidi; Loo, Chee Yean; Mohd, Rozita; Zainudin, Soehardy; Shah, Shamsul Azhar; Norella, Kong Chiew Tong.

In: Nephrology, Vol. 14, No. 5, 08.2009, p. 488-492.

Research output: Contribution to journalArticle

Abdul Gafor, Abdul Halim ; Saidin, Rashidi ; Loo, Chee Yean ; Mohd, Rozita ; Zainudin, Soehardy ; Shah, Shamsul Azhar ; Norella, Kong Chiew Tong. / Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism. In: Nephrology. 2009 ; Vol. 14, No. 5. pp. 488-492.
@article{ee9a4eef86da40b197df8c397b64bb28,
title = "Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism",
abstract = "Aim: Secondary hyperparathyroidism (SHPT) is common among haemodialysis patients. Intensive treatment with calcitriol is often complicated by hypercalcaemia, hyperphosphataemia and elevated calcium phosphorus (Ca X PO 4) product. Paricalcitol is a vitamin D analogue developed to overcome some of the limitations of calcitriol therapy. The study objectives were to compare the response of intact parathyroid hormone (iPTH) and the incidence of hypercalcaemia, hyperphosphataemia and elevated Ca X PO4 product in patients with severe SHPT treated with either i.v. calcitriol or i.v. paricalcitol. Methods: This was a single centre randomized open label study. Patients with serum intact iPTH of 50 pmol/L or more were randomized to receive either i.v. calcitriol (0.01 ug/kg) or i.v. paricalcitol (0.04 ug/kg) during every haemodialysis treatment. Serum iPTH, calcium, phosphorus and alkaline phosphatase were measured at the beginning of the study and every 3 weeks for 12 weeks. Results: Twenty-five patients were enrolled into the study - 12 were randomized into the calcitriol group and 13 into the paricalcitol group. There were no differences in the baseline study parameters between both groups. Serum iPTH levels were significantly reduced (P = 0.003) only in the paricalcitol group but not in the calcitriol group (P = 0.101). On the other hand, serum calcium levels were significantly increased only in the calcitriol group (P = 0.004 vs P = 0.242). Serum phosphorus, alkaline phosphatase and Ca X PO4 product were not different. Conclusion: Intravenous paricalcitol may be superior to i.v. calcitriol for the treatment of severe SHPT in our chronic haemodialysis population. A larger randomized controlled trial is indicated to confirm these initial findings.",
keywords = "Calcium, Calcium phosphorus product, Haemodialysis, Parathyroid hormone, Phosphate",
author = "{Abdul Gafor}, {Abdul Halim} and Rashidi Saidin and Loo, {Chee Yean} and Rozita Mohd and Soehardy Zainudin and Shah, {Shamsul Azhar} and Norella, {Kong Chiew Tong}",
year = "2009",
month = "8",
doi = "10.1111/j.1440-1797.2008.01058.x",
language = "English",
volume = "14",
pages = "488--492",
journal = "Nephrology",
issn = "1320-5358",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism

AU - Abdul Gafor, Abdul Halim

AU - Saidin, Rashidi

AU - Loo, Chee Yean

AU - Mohd, Rozita

AU - Zainudin, Soehardy

AU - Shah, Shamsul Azhar

AU - Norella, Kong Chiew Tong

PY - 2009/8

Y1 - 2009/8

N2 - Aim: Secondary hyperparathyroidism (SHPT) is common among haemodialysis patients. Intensive treatment with calcitriol is often complicated by hypercalcaemia, hyperphosphataemia and elevated calcium phosphorus (Ca X PO 4) product. Paricalcitol is a vitamin D analogue developed to overcome some of the limitations of calcitriol therapy. The study objectives were to compare the response of intact parathyroid hormone (iPTH) and the incidence of hypercalcaemia, hyperphosphataemia and elevated Ca X PO4 product in patients with severe SHPT treated with either i.v. calcitriol or i.v. paricalcitol. Methods: This was a single centre randomized open label study. Patients with serum intact iPTH of 50 pmol/L or more were randomized to receive either i.v. calcitriol (0.01 ug/kg) or i.v. paricalcitol (0.04 ug/kg) during every haemodialysis treatment. Serum iPTH, calcium, phosphorus and alkaline phosphatase were measured at the beginning of the study and every 3 weeks for 12 weeks. Results: Twenty-five patients were enrolled into the study - 12 were randomized into the calcitriol group and 13 into the paricalcitol group. There were no differences in the baseline study parameters between both groups. Serum iPTH levels were significantly reduced (P = 0.003) only in the paricalcitol group but not in the calcitriol group (P = 0.101). On the other hand, serum calcium levels were significantly increased only in the calcitriol group (P = 0.004 vs P = 0.242). Serum phosphorus, alkaline phosphatase and Ca X PO4 product were not different. Conclusion: Intravenous paricalcitol may be superior to i.v. calcitriol for the treatment of severe SHPT in our chronic haemodialysis population. A larger randomized controlled trial is indicated to confirm these initial findings.

AB - Aim: Secondary hyperparathyroidism (SHPT) is common among haemodialysis patients. Intensive treatment with calcitriol is often complicated by hypercalcaemia, hyperphosphataemia and elevated calcium phosphorus (Ca X PO 4) product. Paricalcitol is a vitamin D analogue developed to overcome some of the limitations of calcitriol therapy. The study objectives were to compare the response of intact parathyroid hormone (iPTH) and the incidence of hypercalcaemia, hyperphosphataemia and elevated Ca X PO4 product in patients with severe SHPT treated with either i.v. calcitriol or i.v. paricalcitol. Methods: This was a single centre randomized open label study. Patients with serum intact iPTH of 50 pmol/L or more were randomized to receive either i.v. calcitriol (0.01 ug/kg) or i.v. paricalcitol (0.04 ug/kg) during every haemodialysis treatment. Serum iPTH, calcium, phosphorus and alkaline phosphatase were measured at the beginning of the study and every 3 weeks for 12 weeks. Results: Twenty-five patients were enrolled into the study - 12 were randomized into the calcitriol group and 13 into the paricalcitol group. There were no differences in the baseline study parameters between both groups. Serum iPTH levels were significantly reduced (P = 0.003) only in the paricalcitol group but not in the calcitriol group (P = 0.101). On the other hand, serum calcium levels were significantly increased only in the calcitriol group (P = 0.004 vs P = 0.242). Serum phosphorus, alkaline phosphatase and Ca X PO4 product were not different. Conclusion: Intravenous paricalcitol may be superior to i.v. calcitriol for the treatment of severe SHPT in our chronic haemodialysis population. A larger randomized controlled trial is indicated to confirm these initial findings.

KW - Calcium

KW - Calcium phosphorus product

KW - Haemodialysis

KW - Parathyroid hormone

KW - Phosphate

UR - http://www.scopus.com/inward/record.url?scp=68349085822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68349085822&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1797.2008.01058.x

DO - 10.1111/j.1440-1797.2008.01058.x

M3 - Article

C2 - 19298641

AN - SCOPUS:68349085822

VL - 14

SP - 488

EP - 492

JO - Nephrology

JF - Nephrology

SN - 1320-5358

IS - 5

ER -